Jackson Creek Investment Advisors LLC Takes $1.46 Million Position in CareDx, Inc (NASDAQ:CDNA)

Jackson Creek Investment Advisors LLC bought a new position in shares of CareDx, Inc (NASDAQ:CDNA) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 121,229 shares of the company’s stock, valued at approximately $1,455,000. CareDx accounts for 0.6% of Jackson Creek Investment Advisors LLC’s investment portfolio, making the stock its 14th biggest position. Jackson Creek Investment Advisors LLC owned about 0.22% of CareDx as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Citigroup Inc. lifted its position in CareDx by 7.1% during the 3rd quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock worth $928,000 after acquiring an additional 8,768 shares in the last quarter. ARK Investment Management LLC grew its position in shares of CareDx by 7.7% in the 4th quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock worth $86,337,000 after acquiring an additional 515,399 shares in the last quarter. First Eagle Investment Management LLC increased its stake in CareDx by 38.7% during the third quarter. First Eagle Investment Management LLC now owns 1,005,189 shares of the company’s stock valued at $7,036,000 after purchasing an additional 280,345 shares during the last quarter. Swiss National Bank lifted its holdings in CareDx by 2.3% in the third quarter. Swiss National Bank now owns 118,200 shares of the company’s stock worth $827,000 after acquiring an additional 2,700 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of CareDx by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,138,591 shares of the company’s stock worth $28,970,000 after purchasing an additional 50,667 shares during the last quarter.

CareDx Price Performance

CDNA stock traded down $0.44 on Tuesday, reaching $7.76. The company’s stock had a trading volume of 825,590 shares, compared to its average volume of 885,470. The firm has a fifty day moving average of $9.61 and a two-hundred day moving average of $9.27. The company has a market capitalization of $401.81 million, a P/E ratio of -2.32 and a beta of 1.42. CareDx, Inc has a 52 week low of $4.80 and a 52 week high of $12.93.

CareDx (NASDAQ:CDNA) last released its earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The company had revenue of $65.57 million for the quarter, compared to analyst estimates of $63.66 million. CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The firm’s quarterly revenue was down 20.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.34) EPS. As a group, equities analysts expect that CareDx, Inc will post -1.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Stephens restated an “overweight” rating and set a $15.00 price objective on shares of CareDx in a research note on Wednesday, April 17th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $13.50.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.